NCT03697161Phase 2Completed

A Study of OV101 in Individuals With Fragile X Syndrome

Study sponsor: Ovid Therapeutics Inc. · OVID

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2020-02-03Actual
Enrollment · participants36Actual
Source updated2024-01-23Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.